# reload+after+2024-01-22 11:46:29.703390
address1§Building F
address2§Suite 320 485 Route 1 South
city§Iselin
state§NJ
zip§08852
country§United States
phone§609 619 3990
website§https://www.outlooktherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
fullTimeEmployees§24
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Ralph H. Thurman', 'age': 74, 'title': 'Independent Executive Chairman', 'yearBorn': 1949, 'fiscalYear': 2022, 'totalPay': 205513, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. C. Russell Trenary III', 'age': 65, 'title': 'President, CEO & Director', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 819530, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Lawrence A. Kenyon CPA', 'age': 57, 'title': 'Executive VP, CFO, Treasurer, Company Secretary & Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jeffrey  Evanson', 'age': 54, 'title': 'Chief Commercial Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 442231, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Alicia  Tozier', 'title': 'Senior Vice President, Marketing & Market Access', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joel  Prieve', 'title': 'Senior Vice President of Licensing and M&A', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Surendra  Sharma M.D.', 'title': 'Senior Vice President of Medical Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jennifer M. Kissner Ph.D.', 'title': 'Senior Vice President of Clinical Development & Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jedd  Comiskey', 'title': 'Senior VP - Head of Europe', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§6
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.216
currency§USD
dateShortInterest§1702598400
forwardEps§-0.21
exchange§NCM
quoteType§EQUITY
shortName§Outlook Therapeutics, Inc.
longName§Outlook Therapeutics, Inc.
firstTradeDateEpochUtc§1465911000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f486d429-2fc2-35f2-aa9e-5e7b4dad8bf2
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§1.0
targetMeanPrice§4.0
targetMedianPrice§2.0
recommendationMean§2.5
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§0.501
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
